Results 81 to 90 of about 20,935 (240)

Trends in new psychoactive substance poisonings in the Netherlands: A 14‐year retrospective analysis (2012–2025)

Addiction, EarlyView.
Abstract Background and aims Data on the presence of new psychoactive substances (NPS) mainly originate from drug‐checking, law enforcement and wastewater analysis sources, while data on NPS poisonings are scarce. In Europe, the documented incidence rate of NPS poisonings is highest in the Netherlands.
Johanna J. Nugteren‐van Lonkhuyzen, Irma S. van den Hengel‐Koot, Claudine C. Hunault, Dylan W. de Lange, Antoinette J. H. P. van Riel, Laura Hondebrink   +5 more
wiley   +1 more source

Cannabis consumer responses to the concept of standard THC units

Addiction, EarlyView.
Abstract Aims Within a context of considerable cannabis market expansion and product diversification, cannabis consumers must manage their use across a range of potencies and modes of consumption. This study aimed to provide deeper understandings of how cannabis consumers would perceive the introduction of a standard THC (tetrahydrocannabinol) unit ...
Mark Pawson, Mike Vuolo, Brian C. Kelly
wiley   +1 more source

Beyond abstinence: Redefining success in cannabis use disorder treatment

Addiction, EarlyView.
Abstract Background Over two decades of pharmacotherapy research has yet to yield a consistently effective medication for cannabis use disorder (CUD), in part because clinical trials have frequently prioritized abstinence as a primary or key endpoint.
Tobias B. Atkin, Frances R. Levin, John Mariani, Christina A. Brezing   +3 more
wiley   +1 more source

Weighted prevalence of biochemically verified substance use in healthy adolescents across the USA

Addiction, EarlyView.
Abstract Background and aims Adolescent substance use is a significant public health concern, though the scope of the problem is difficult to ascertain given reliance on self‐reported substance use information. Recent, large cohort studies in adolescents and young adults suggest underreporting of substance use.
Natasha E. Wade, Yajuan Si, Susan F. Tapert, Janosch Linkersdörfer, Krista M. Lisdahl, Hailley R. Moore, Laila Tally, Biplabendu Das, Marilyn A. Huestis, Alexander L. Wallace, Ryan M. Sullivan, Veronica Szpak, Le Zhang, Laura Ziemer, Wesley K. Thompson   +14 more
wiley   +1 more source

Tetrahydrocannabinolic Acid, a Genuine Substance of Tetrahydrocannabinol

Chemical and Pharmaceutical Bulletin, 1967
Yamauchi, Tatsuo, Shoyama, Yukihiro, Aramaki, Hanichiro, Azuma, Tomoko, Nishioka, Itsuo   +4 more
openaire   +3 more sources

Cannabis use disorder in patients prescribed medical cannabis—Should we consider prescription cannabis use disorder as a new diagnostic condition?

Addiction, EarlyView.
Abstract Background and Aims The introduction of prescribed medical cannabis in many parts of the world raises issues regarding how we conceptualise Cannabis Use Disorders (CUD). The Diagnostic Statistical Manual Version 5 (DSM5) provides a framework for ‘Prescription Cannabis Use Disorder’ (Pr‐CUD) when a person is using medical cannabis only‐as ...
Nicholas Lintzeris, Llewellyn Mills
wiley   +1 more source

Do motives for and contexts of cannabis use interact to predict heavy cannabis use at the event‐level?

The American Journal on Addictions, EarlyView.
Abstract Background and Objectives Motives for and contexts of cannabis use (CU) are typically examined as independent characteristics of CU events in ecological momentary assessment (EMA) studies. However, theories posit that some combinations of motives and contexts (e.g., using to cope in a solitary setting) may contribute to heavier substance use ...
Christina Dyar, Elise Green, Christine M. Lee   +2 more
wiley   +1 more source

Tetrahydrocannabinol and Cannabidiol for Pain Treatment—An Update on the Evidence

Biomedicines
In light of the current International Association for the Study of Pain (IASP) clinical practice guidelines (CPGs) and the European Society for Medical Oncology (ESMO) guidelines, the topic of cannabinoids in relation to pain remains controversial, with ...
Kawthar Safi, Jan Sobieraj, Michał Błaszkiewicz, Joanna Żyła, Bartłomiej Salata, Tomasz Dzierżanowski   +5 more
doaj   +1 more source

Toxicokinetic modelling of the synthetic cannabinoid 5F‐MDMB‐P7AICA and its main metabolite in pigs following pulmonary administration

British Journal of Clinical Pharmacology, EarlyView.
Aims Since their emergence on the drug market, synthetic cannabinoids (SC) are still gaining increasing importance in forensic toxicology. The representatives of the so‐called new psychoactive substances have in common that they have not undergone preclinical safety studies. Hence, knowledge on toxicokinetic (TK) data is sparse.
Adrian A. Doerr, Christiane Dings, Omar Zaher, Frederike Nordmeier, Nadja Walle, Matthias W. Laschke, Michael D. Menger, Peter H. Schmidt, Markus R. Meyer, Thorsten Lehr, Nadine Schaefer   +10 more
wiley   +1 more source

The Cannabinoid Pharmacology of Bone Healing: Developments in Fusion Medicine

Biomedicines
Background/Objectives: Cannabinoid use is rising among patients undergoing spinal fusion, yet its influence on bone healing is poorly defined. The endocannabinoid system (ECS)—through cannabinoid receptors 1 (CB1) and 2 (CB2)—modulates skeletal ...
Gabriel Urreola, Michael Le, Alan Harris, Jose A. Castillo, Augustine M. Saiz, Hania Shahzad, Allan R. Martin, Kee D. Kim, Safdar Khan, Richard Price   +9 more
doaj   +1 more source